Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs02315016
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
---|---|---|---|---|---|
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
485 | [2-AMINO-3-(4-HYDROXY-PHENYL)-PROPIONYLAMINO]- (3,4,5-TRIHYDROXY-6-METHYL-TETRAHYDRO- PYRAN-2-YL)- ACETIC ACID | A | 1JIL | 0.74 | |
IYT | N-ALPHA-ACETYL-3,5-DIIODOTYROSYL- D-THREONINE | A | 1SDW | 0.72 | |
GB1 | (2R,3R,4S)-2-({[(1R)-2-HYDROXY- 1-PHENYLETHYL]AMINO}METHYL)PYRROLIDINE- 3,4-DIOL | A | 2F18 | 0.75 | |
NYS | S-{5-[(1R)-2-amino-1-hydroxyethyl]- 2,3-dihydroxyphenyl}-L-cysteine | B | 2R1V | 0.73 | |
545 | [2-AMINO-3-(4-HYDROXY-PHENYL)-PROPIONYLAMINO]- (1,3,4,5-TETRAHYDROXY-4-HYDROXYMETHYL- PIPERIDIN-2-YL)- ACETIC ACID BUTYL ESTER | A | 1JIK | 0.72 | |
383 | [2-AMINO-3-(4-HYDROXY-PHENYL)-PROPIONYLAMINO]- (2,4,5,8-TETRAHYDROXY-7-OXA-2- AZA-BICYCLO[3.2.1]OCT-3-YL)- ACETIC ACID | A | 1JII | 0.72 | |
GB2 | (2R,3R,4S)-2-({[(1S)-2-HYDROXY- 1-PHENYLETHYL]AMINO}METHYL)PYRROLIDINE- 3,4-DIOL | A | 2F1A | 0.75 | |
0E4 | N-acetyl-L-tyrosyl-L-valyl-L-alanyl- L-aspartic acid | B,D | 3GJS | 0.7 | |
CMQ | N~2~-[(BENZYLOXY)CARBONYL]-N-[(1S,2S)- 2-HYDROXY-1-(4-HYDROXYBENZYL)PROPYL]- L-LEUCINAMIDE | A,B,C,D,E,F, G,H,I,J,K,L, M,N | 2FZS | 0.72 | |
PIR | 2-(4-AMINO-PHENYL)-5-HYDROXYMETHYL- PYRROLIDINE-3,4-DIOL | A,B,C,D | 2MAS | 0.7 | |
DAH | 3,4-DIHYDROXYPHENYLALANINE | A,B | 1RNR | 0.75 | |
DAH | 3,4-DIHYDROXYPHENYLALANINE | A | 6PAH | 0.75 | |
DAH | 3,4-DIHYDROXYPHENYLALANINE | A,B | 1IVV | 0.75 | |
AHT | 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)- PHENOL | I,T | 1TMB | 0.76 | |
ANM | ANISOMYCIN | 1,2,4,A,B,C, D,E,J,K,L,M, N,O,P,R,S,T, U,V,Z | 1K73 | 0.76 | |
ANM | ANISOMYCIN | 0,1,3,9,A,B, C,F,H,J,K,L, M,N,O,Q,R,S, T,U,Y,Z | 3CC4 | 0.76 | |
RHP | (3R)-3-(PROP-2-YNYLAMINO)INDAN- 5-OL | A,B | 1S3E | 0.72 | |
NLT | N-DODECANOYL-L-TYROSINE | A,B,C,D,E,F, G,H | 2G0B | 0.71 | |
OTS | 4-(2S-AMINO-1-HYDROXYETHYL)PHENOL | A,B | 1RG2 | 0.78 | |
OTS | 4-(2S-AMINO-1-HYDROXYETHYL)PHENOL | A,B | 1RG1 | 0.78 | |
OTS | 4-(2S-AMINO-1-HYDROXYETHYL)PHENOL | A,B | 1RH0 | 0.78 | |
OTS | 4-(2S-AMINO-1-HYDROXYETHYL)PHENOL | A,B | 1RGU | 0.78 | |
OTS | 4-(2S-AMINO-1-HYDROXYETHYL)PHENOL | A,B | 1RGT | 0.78 | |
CCY | 2-(1-AMINO-2-MERCAPTO-ETHYL)-5- (4-HYDROXY-BENZYL)-3-(ETHANOYL)- 3,5-DIHYDRO-IMIDAZOL-4-ONE | A | 1EMK | 0.71 | |
ALE | L-EPINEPHRINE | A | 3PAH | 0.91 | |
ALE | L-EPINEPHRINE | A | 2HKK | 0.91 | |
TYP | CYCLO-(L-TYROSINE-L-PROLINE) INHIBITOR | A,B | 1W1Y | 0.73 | |
OTR | 4-(2R-AMINO-1-HYDROXYETHYL)PHENOL | A,B | 1RGT | 0.78 | |
OTR | 4-(2R-AMINO-1-HYDROXYETHYL)PHENOL | A,B | 1RG2 | 0.78 | |
OTR | 4-(2R-AMINO-1-HYDROXYETHYL)PHENOL | A,B | 2AN4 | 0.78 | |
AEF | 4-(2-aminoethyl)phenol | A | 3BRA | 0.71 | |
099 | (2R)-N~4~-hydroxy-2-(3-hydroxybenzyl)- N~1~-[(1S,2R)-2-hydroxy-2,3-dihydro- 1H-inden-1-yl]butanediamide | A,B | 3HYG | 0.7 | |
GB3 | (2R,3R,4S,5R)-2-({[(1R)-2-HYDROXY- 1-PHENYLETHYL]AMINO}METHYL)-5-METHYLPYRROLIDINE- 3,4-DIOL | A | 2F1B | 0.76 | |
629 | [2-AMINO-3-(4-HYDROXY-PHENYL)-PROPIONYLAMINO]- (1,3,4,5-TETRAHYDROXY-4-HYDROXYMETHYL- PIPERIDIN-2-YL)- ACETIC ACID | A | 1JIJ | 0.74 | |
Y13 | (2E)-3-(3,4-DIHYDROXYPHENYL)-N- [2-(4-HYDROXYPHENYL)ETHYL]ACRYLAMIDE | A | 2EW6 | 0.73 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A,B | 2AH8 | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A,B,C,D | 1HCJ | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A,B,C,D | 1W7S | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A,B,C,D | 1W7T | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A,B | 2AHA | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A | 1EME | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A,B | 1KP5 | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A | 1EMM | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A | 1EML | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A,B,C,D | 1W7U | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A,B,C,D | 1EMC | 0.75 | |
CSY | [4-(4-HYDROXY-BENZYL)-2-(2-HYDROXY- 1-METHYL-ETHYL)-5-OXO-IMIDAZOLIDIN- 1-YL]-ACETIC ACID | A | 2HPW | 0.75 | |
2TN | 2-(4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ETHANAMIDE | A | 2OTF | 0.71 | |
2TN | 2-(4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ETHANAMIDE | A | 2NUV | 0.71 | |
2TN | 2-(4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ETHANAMIDE | A | 2OUB | 0.71 | |
5RM | (5R)-5-(4-methoxy-3-propoxyphenyl)- 5-methyl-1,3-oxazolidin-2-one | A,B | 1XM6 | 0.71 | |
LNR | L-NOREPINEPHRINE | A,B | 2QEO | 0.85 | |
LNR | L-NOREPINEPHRINE | A | 3DYE | 0.85 | |
LNR | L-NOREPINEPHRINE | A | 4PAH | 0.85 | |
TYB | TYROSINAL | A,B | 1KDZ | 0.7 | |
TYB | TYROSINAL | A | 1Q11 | 0.7 | |
TYB | TYROSINAL | A,B | 2J5B | 0.7 | |
TYB | TYROSINAL | A,I | 1GA4 | 0.7 | |
TYB | TYROSINAL | A,B,C | 1NLU | 0.7 | |
TYB | TYROSINAL | A,B | 1KE1 | 0.7 | |
TYB | TYROSINAL | A,B | 1H3F | 0.7 | |
TYB | TYROSINAL | A,B | 1H3E | 0.7 | |
AEG | 4-[(2R)-2-aminopropyl]phenol | A | 3BUF | 0.74 | |
CZO | [(2R,4S)-2-[(1S,2R)-1-amino-2-hydroxypropyl]- 2-hydroxy-4-(4-hydroxybenzyl)-5- oxoimidazolidin-1-yl]acetic acid | A | 2QRF | 0.75 | |
LDP | L-DOPAMINE | A,B | 2A3R | 0.79 | |
LDP | L-DOPAMINE | A | 5PAH | 0.79 | |
LDP | L-DOPAMINE | A,B | 2QMZ | 0.79 | |
LDP | L-DOPAMINE | A,B | 2VQ5 | 0.79 | |
MTY | META-TYROSINE | A | 2TOH | 0.71 | |
MTY | META-TYROSINE | A,B | 1BIQ | 0.71 | |
MTY | META-TYROSINE | A | 1Q7O | 0.71 | |
SAF | 3-[(1S)-1-(DIMETHYLAMINO)ETHYL]PHENOL | A | 1GQR | 0.72 | |
SAF | 3-[(1S)-1-(DIMETHYLAMINO)ETHYL]PHENOL | A | 1GQS | 0.72 | |
PI5 | N-[3-(8-SEC-BUTYL-7,10-DIOXO-2- OXA-6,9-DIAZA-BICYCLO[11.2.2]HEPTADECA- 1(16),13(17),14- TRIEN-11-YLAMINO)- 2-HYDROXY-1-(4-HYDROXY-BENZYL)- PROPYL]-3-METHYL-2- (2-OXO-PYRROLIDIN- 1-YL)-BUTYRAMIDE | A,B | 1B6K | 0.7 | |
SD2 | N-(SULFANYLACETYL)TYROSYLPROLYLMETHIONINAMIDE | A,B | 1PWQ | 0.7 | |
AEH | 4-(2-aminoethyl)-2-ethylphenol | A | 3BUG | 0.71 | |
TY3 | 3-HYDROXY-L-TYROSINE | A,B | 2VH3 | 0.75 | |
TYC | L-TYROSINAMIDE | A | 2BF9 | 0.7 | |
TYC | L-TYROSINAMIDE | A | 2OCI | 0.7 | |
CJO | [(2R,4R)-2-[(1R,2R)-1-amino-2-hydroxypropyl]- 4-(4-hydroxybenzyl)-5-oxoimidazolidin- 1-yl]acetic acid | A | 2QT2 | 0.76 |